Lung Cancer

Share

Program Content

Activities

  • Conference to Clinic: Lung Cancer
    Conference to Clinic: Lung Cancer
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 16, 2023

  • Conference to Clinic: Lung Cancer
    Conference to Clinic: Expert Analysis of the Top Lung Cancer Abstracts From the 2023 Oncology Meeting in Chicago
    Video
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 29, 2023

    Expires: June 28, 2024

  • Lung Cancer Highlights: ASCO 2023
    Key Studies in Lung Cancer: Independent Conference Coverage of ASCO 2023
    Conference Coverage
    Text Module
    Congratulations: You achieved a completion on 04/09/2022

    Released: August 25, 2023

    Expires: August 24, 2024

Activities

KEYNOTE-671
KEYNOTE-671: Pembrolizumab or Placebo + Platinum-Based Neoadjuvant Chemotherapy Followed by Resection and Adjuvant Pembrolizumab or Placebo in Early-Stage NSCLC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 08, 2023

CheckMate 9LA: 4-Yr Update
CheckMate 9LA: 4-Yr Update of First-line Nivolumab + Ipilimumab + CT vs CT Alone in Advanced NSCLC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 08, 2023

TROPION-Lung02
TROPION-Lung02: Datopotamab Deruxtecan + Pembrolizumab ± Platinum Chemotherapy in Advanced NSCLC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 08, 2023

KEYNOTE-789
Phase III KEYNOTE-789: Pemetrexed/Platinum Chemotherapy ± Pembrolizumab in TKI-Resistant, EGFR-Mutated, Metastatic Nonsquamous NSCLC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2023

Neoadjuvant Osimertinib in EGFRm NSCLC
Phase II Trial of Neoadjuvant Osimertinib in Stage I-IIIA EGFR-Mutated NSCLC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2023

INSIGHT 2 Trial Results
INSIGHT 2: Tepotinib + Osimertinib for Advanced EGFR-Mutated NSCLC With MET Amplification Following First-line Osimertinib
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2023

ADAURA: Final OS Analysis
ADAURA: OS Analysis of Adjuvant Osimertinib vs Placebo After Complete Resection in Stage IB-IIIA EGFR-Mutated NSCLC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2023

LUNAR: TTFields in NSCLC
Phase III LUNAR: Tumor Treating Fields + Standard Second-line Therapy in Metastatic NSCLC With Progression On/After Platinum-Based Therapy
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 12, 2023

SWOG S1929
Phase II SWOG S1929: Maintenance Atezolizumab ± Talazoparib for SLFN11-Positive Extensive-Stage SCLC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2023

AGAIN
Phase III AGAIN (JCOG1404/WJOG8214L) Trial: First-line EGFR-TKI Monotherapy vs EGFR-TKI and Inserted Cisplatin/Pemetrexed in Advanced Nonsquamous, EGFR-Mutated NSCLC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2023

NEOTORCH
Phase III NEOTORCH: Interim EFS Analysis of Perioperative Toripalimab + Platinum-Doublet CT vs Platinum-Doublet CT in Resectable Stage II/III NSCLC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 06, 2023

Pembro + CT in Pleural Mesothelioma
Phase III Trial of Pembrolizumab + Chemotherapy vs Chemotherapy Alone in Treatment-Naive Pleural Mesothelioma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 07, 2023

Faculty

cover img faculity

Karen Reckamp, MD, MS

Director, Division of Medical Oncology
Associate Director of Clinical Research
Professor of Medicine
Cedars Sinai
Los Angeles, California

cover img faculity

Heather Wakelee, MD, FASCO

Professor of Medicine
Department of Medicine/Oncology
Stanford University
Stanford University Cancer Institute
Stanford, California 

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Merck Sharp & Dohme Corp., and Novocure.

AstraZeneca

Daiichi Sankyo

Merck Sharp & Dohme Corp.

Novocure